Show simple item record

dc.contributor.authorOrishaba, Philip
dc.contributor.authorKalyango, Joan N.
dc.contributor.authorByakika-Kibwika, Pauline
dc.contributor.authorArinaitwe, Emmanuel
dc.contributor.authorWandera, Bonnie
dc.contributor.authorKatairo, Thomas
dc.contributor.authorMuzeyi, Wani
dc.contributor.authorTendo Nansikombi, Hildah
dc.contributor.authorNakato, Alice
dc.contributor.authorMutabazi, Tobius
dc.contributor.authorKamya, Moses R.
dc.contributor.authorDorsey, Grant
dc.contributor.authorNankabirwa, Joaniter I.
dc.date.accessioned2022-01-12T11:38:11Z
dc.date.available2022-01-12T11:38:11Z
dc.date.issued2020
dc.identifier.citationOrishaba P, Kalyango JN, Byakika- Kibwika P, Arinaitwe E, Wandera B, Katairo T, et al. (2020) Increased malaria parasitaemia among adults living with HIV who have discontinued cotrimoxazole prophylaxis in Kitgum district, Uganda. PLoS ONE 15(11): e0240838. https://doi. org/10.1371/journal.pone.0240838en_US
dc.identifier.urihttps://doi. org/10.1371/journal.pone.0240838
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1221
dc.description.abstractAlthough WHO recommends cotrimoxazole (CTX) discontinuation among HIV patients who have undergone immune recovery and are living in areas of low prevalence of malaria, some countries including Uganda recommend CTX discontinuation despite having a high malaria burden. We estimated the prevalence and factors associated with malaria parasitaemia among adults living with HIV attending hospital outpatient clinic before and after discontinuation of CTX prophylaxis.en_US
dc.language.isoenen_US
dc.publisherPLoS ONEen_US
dc.subjectMalaria parasitaemiaen_US
dc.subjectAdultsen_US
dc.subjectHIVen_US
dc.subjectCotrimoxazole prophylaxisen_US
dc.subjectUgandaen_US
dc.titleIncreased malaria parasitaemia among adults living with HIV who have discontinued cotrimoxazole prophylaxis in Kitgum district, Ugandaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record